logo
The American Fast Food Chain That's More Beloved By Our Northern Neighbors In Canada

The American Fast Food Chain That's More Beloved By Our Northern Neighbors In Canada

Yahoo17-05-2025

If you've ever gone on a road trip through Canada, you've probably passed by dozens of A&W locations –- and if you're lucky, popped in for a Teen Burger. Unlike in the United States, where the brand is just one of many fast-food burger chains, A&W is a big deal in Canada.
Despite having only a fraction of the United States' population, Canada has more than twice as many A&W locations. Known for its ice-cold root beer, a lawsuit over aged vanilla in bottled soda, and an orange-sweater-clad bear mascot, Rooty, A&W is one of the most popular fast food chains in Canada, with approximately 1,050 nationwide, making it almost as ubiquitous as McDonald's, which has just over 1,400 stores across the country. Canucks love A&W, and for good reason –- the Canadian locations are all Canadian-owned and tastes delicious.
Thanks to the 2025 trade war between the United States and Canada, A&W has become even more popular up north. Canadians have shared their love for A&W online and encouraged others to embrace the chain as an alternative to American fast food burger chains like McDonald's and Wendy's. After all, it's well documented on Reddit that A&W tastes better up North.
Read more: Ranking Fast Food Burgers From Worst To Best, According To Reddit
To understand why A&W in Canada is different from the United States, you need to know its history. The fast food chain can trace its beginnings to 1919, when Roy W. Allen started a roadside root beer stand in Lodi, California. In 1922, Allen teamed up with his root beer stand employee, Frank Wright, and A&W was born, becoming one of the first franchised fast food restaurant pioneers in the United States in 1926.
The company continued to expand both domestically and internationally, arriving in Winnipeg, Manitoba, in 1956. However, in 1972, Unilever purchased all of the Canadian franchises, officially separating A&W Canada from its U.S. and other international locations.
So, while you'll find ice-cold root beer and Rooty's smiling face at locations on both sides of the border, A&W Canada is essentially a completely different entity, with unique menu items that you won't find stateside, like poutine, Canada's unofficial national dish and the cult-favorite Mozza Burger, which is topped with bacon and real mozzarella cheese. In addition to burgers and chicken, A&W in Canada offers an extensive breakfast menu.
The brand has also been vocal about using grass- or vegetarian-fed beef, pork, and chicken -- all of which are humanely raised on local family farms (or select, quality ranches), which may explain why their signature burgers allegedly taste better than the American versions. This is undoubtedly the case with the Teen Burger, an ultra-juicy bacon and cheese burger made with cheddar cheese and something called "teen sauce" (a mayo that's well seasoned with a punch of mustard), which has been called "pretty much the perfect fast food burger" (per Reddit). Strong words that may require a trip over the border.
Want more food knowledge? Sign up to our free newsletter where we're helping thousands of foodies, like you, become culinary masters, one email at a time.
Read the original article on Food Republic.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Macquarie's $3.6 billion S. Korean gas firm draws interest from KKR, Brookfield and industry peers, sources say
Macquarie's $3.6 billion S. Korean gas firm draws interest from KKR, Brookfield and industry peers, sources say

Yahoo

time41 minutes ago

  • Yahoo

Macquarie's $3.6 billion S. Korean gas firm draws interest from KKR, Brookfield and industry peers, sources say

By Kane Wu and Yantoultra Ngui HONG KONG/SINGAPORE (Reuters) -Potential bidders for Macquarie Asset Management's South Korean industrial gas firm DIG Airgas include investment firm KKR & Co, Brookfield Asset Management, and French gas supplier Air Liquide, in a deal that could fetch up to $3.6 billion, two sources with knowledge of the matter said. Macquarie has hired Goldman Sachs and JPMorgan to run the sale and is expecting non-binding bids this month, the sources said, declining to be named as the information is not public. DIG Airgas, South Korea's third-largest industrial gas producer, has also attracted interest from infrastructure funds including I Squared Capital and Stonepeak, and U.S.-based global gas and chemical firm Air Products, said the sources. The Seoul-headquartered company has about $170 million to $180 million in earnings before interest, taxes, depreciation, and amortisation (EBITDA), and Macquarie expects a sale to value the firm at 18-20 times core earnings, said one of the sources. DIG Airgas and Air Liquide did not immediately respond to requests for comment. Macquarie, JPMorgan, Goldman Sachs, KKR, Brookfield, I Squared Capital and Stonepeak declined to comment. Air Products declined to comment on the sale. "South Korea is a vital and growing market, and Air Products remains committed to growing its industrial gas business serving customers safely and reliably," its spokesperson said. Established in 1979, DIG Airgas produces industrial gases, electronic gases and gas equipment, according to its website. Macquarie bought the company, formerly known as Dausung Industrial Gases, from South Korean private equity firm MBK Partners for 2.5 trillion won ($1.85 billion) in 2019, local media reported at the time. ($1 = 1,351.8900 won)

Capital Increase Reserved for Employees of TotalEnergies in 2025
Capital Increase Reserved for Employees of TotalEnergies in 2025

Yahoo

timean hour ago

  • Yahoo

Capital Increase Reserved for Employees of TotalEnergies in 2025

PARIS, June 10, 2025--(BUSINESS WIRE)-- In accordance with its policy in favour of employee shareholding, the Board of Directors of TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE) decided, on October 30, 2024, to carry out a capital increase reserved for eligible employees and former employees of TotalEnergies SE and its French and foreign subsidiaries in which the Company holds directly or indirectly more than 50% (in terms of capital or voting rights), that are members of the PEG-A Group savings plan, in France and abroad, under the conditions set by the twenty-second resolution at the Shareholders' Meeting of May 24, 2024. On April 29, 2025, the Chairman and CEO set (i) the subscription period from May 2 to May 15, 2025 (included) and (ii) the subscription price at 42.50 euros per share, corresponding to the average of the closing prices of the TotalEnergies share on Euronext over the twenty trading sessions preceding the date of this decision, reduced by a 20% discount and rounded off to the highest tenth of a euro. At the end of this period, 62,796 employees in 97 countries, representing 53% of the eligible employees and former employees, subscribed to this capital increase for an amount of 449.3 million euros. The 2025 results are close to those of 2024, a record year, and significantly higher than in previous years, both in terms of participation and amounts subscribed. "Employee share ownership is the best way to associate employees with the economic performance of the company, strengthen their sense of belonging and align the interests of employees and shareholders. Employees responded this year again massively to the capital increase reserved for them, and increasingly so, investing nearly 450 million euros, an amount close to last year's record of 480 million euros, and around 100 million more than the amounts of 2021, 2022, and 2023. These figures reflect an increase of 10,000 subscribers since 2024, when all employees received 100 shares to celebrate the 100th anniversary of the Company. It demonstrates that our employees have a strong and lasting confidence in their company and its strategy. This strong momentum has once again enabled TotalEnergies to confirm its position as the number one in employee shareholding in Europe in terms of capitalization held, and it was awarded with the 'Grand Prix' from the French Federation of Employee Shareholding", declared Patrick Pouyanné, Chairman and CEO of TotalEnergies. As a result, 11,149,053 new shares are being issued on June 10, 2025. They will carry immediate dividend rights and will be fully assimilated with TotalEnergies shares already listed on Euronext. Following this issuance, the employee shareholders in TotalEnergies SE's share capital, within the meaning of Article L. 225-102 of the French Commercial Code, is estimated at 8.8% of the Company's share capital as of June 10, 2025. About TotalEnergies TotalEnergies is a global integrated energy company that produces and markets energies: oil and biofuels, natural gas, biogas and low-carbon hydrogen, renewables and electricity. Our more than 100,000 employees are committed to provide as many people as possible with energy that is more reliable, more affordable and more sustainable. Active in about 120 countries, TotalEnergies places sustainability at the heart of its strategy, its projects and its operations. TotalEnergiesMedia Relations: +33 (0)1 47 44 46 99 l presse@ l @TotalEnergiesPR Investor Relations: +33 (0)1 47 44 46 46 l ir@ X @TotalEnergies LinkedIn TotalEnergies Facebook TotalEnergies Instagram TotalEnergies Cautionary Note The terms "TotalEnergies", "TotalEnergies company" or "Company" in this document are used to designate TotalEnergies SE and the consolidated entities that are directly or indirectly controlled by TotalEnergies SE. Likewise, the words "we", "us" and "our" may also be used to refer to these entities or to their employees. The entities in which TotalEnergies SE directly or indirectly owns a shareholding are separate legal entities. TotalEnergies SE has no liability for the acts or omissions of these entities. This document may contain forward-looking information and statements that are based on a number of economic data and assumptions made in a given economic, competitive and regulatory environment. They may prove to be inaccurate in the future and are subject to a number of risk factors. Neither TotalEnergies SE nor any of its subsidiaries assumes any obligation to update publicly any forward-looking information or statement, objectives or trends contained in this document whether as a result of new information, future events or otherwise. Information concerning risk factors, that may affect TotalEnergies' financial results or activities is provided in the most recent Registration Document, the French-language version of which is filed by TotalEnergies SE with the French securities regulator Autorité des Marchés Financiers (AMF), and in the Form 20-F filed with the United States Securities and Exchange Commission (SEC). View source version on Contacts TotalEnergies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore
ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore

Yahoo

timean hour ago

  • Yahoo

ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore

SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedTech ventures in Singapore. This partnership will support venture creation, product development, and commercialisation by bringing together ClavystBio and two national initiatives hosted by A*STAR — MedTech Catapult and the Diagnostics Development Hub (DxD Hub) — along with A*STAR's broader MedTech and venture creation capabilities. The partnership comes amid growing momentum in Singapore's biomedical landscape, with MedTech output reaching S$20 billion in 2023.[1] As Asia's MedTech market is projected to grow to US$225 billion (S$304 billion) by 2030,[2] these efforts aim to better position Singapore-based innovations to scale and enter new markets. Over this two-year partnership, the parties will work towards the co-creation of new MedTech ventures, investments into A*STAR affiliated companies, and fostering collaborations between A*STAR and ClavystBio's portfolio companies. By combining complementary strengths — from research and engineering to venture building and funding — the partnership aims to identify promising technologies, shape MedTech projects for market readiness, and support new venture formation to strengthen Singapore's innovation-driven MedTech ecosystem. The partnership will focus on several key areas: Fostering new ventures from research: A*STAR and ClavystBio will jointly identify promising research and technologies to venture build new MedTech companies. A*STAR will contribute deep scientific expertise and structured venture creation support, while ClavystBio will provide access to venture and growth capital, expert guidance, and its extensive network to launch and scale these early-stage companies. Advancing MedTech product development: MedTech Catapult will support the development of medical devices through engineering design, prototyping, and manufacturing translation, while ClavystBio will draw on its investment and industry relationships to explore potential commercial pathways for promising innovations. Accelerating commercial readiness in diagnostics and digital health: DxD Hub and ClavystBio will shape ventures in this space with strong commercial potential. DxD Hub will bring technical and productisation expertise — including in AI-powered software, multi-omics, and point-of-care diagnostics — to refine innovations for commercial viability. ClavystBio will contribute its venture investing and venture building expertise to drive commercialisation. Strengthening Singapore's MedTech ecosystem: To support long-term sector growth, the partners will assess Singapore's MedTech manufacturing, design, and regulatory support landscape. MedTech Catapult will lead efforts to map ecosystem capabilities and identify gaps, while ClavystBio will explore investment opportunities in companies with specialised technologies that can strengthen Singapore's MedTech value chain. "This partnership highlights ClavystBio's commitment to nurturing globally successful medical devices, digital health, and diagnostics companies from Singapore," said Mr Anselm Tan, Digital Health & MedTech Lead at ClavystBio. "By combining ClavystBio's investment and venture-building expertise with A*STAR's deep scientific capabilities and productisation platforms, we are cultivating an ecosystem primed for innovation and commercial success. "A*STAR is committed to nurturing a dynamic MedTech ecosystem that bridges innovation with deep tech companies," said Ms Irene Cheong, Assistant Chief Executive (Innovation & Enterprise) at A*STAR. "This MoU builds on an existing collaboration with ClavystBio and marks a significant step forward in our joint efforts to co-create and grow globally investible MedTech ventures. Through national productisation platforms like MedTech Catapult and DxD Hub, combined with A*STAR's venture creation capabilities, we aim to commercialise more innovations from lab to market and grow a vibrant MedTech ecosystem in Singapore." [1] Speech by SMS Low Yen Ling at the MedTech Forum[2] Singapore's MedTech sector and locally made medical devices punching above their weight | Singapore EDB About ClavystBio ClavystBio is a life sciences investor and venture builder set up by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing start-ups together, we foster a vibrant and supportive community. About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit About Diagnostics Development Hub (DxD Hub) The Diagnostics Development Hub is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub aims to accelerate the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption. Through impactful products, empowering local enterprises and anchoring global companies in Singapore, DxD Hub contributes to the development of an effective diagnostic devices' ecosystem in Singapore. For ongoing news, visit About MedTech Catapult MedTech Catapult (MC) is a national initiative designed to accelerate the product development and commercialisation of high-value life science instruments and regulated medical devices. MC partners with product owners, local contract manufacturers (CMs), and leverages external design houses, and other key stakeholders to guide innovations from concept to market. Their goal is to strengthen Singapore's medtech ecosystem by providing dedicated engineering, quality assurance, regulatory affairs, clinical affairs, project management and commercialisation support to derisk and support products towards commercialisation and market adoption whilst supporting pull-through to local manufacturing. View original content to download multimedia: SOURCE ClavystBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store